Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.09.014Source: DataRank Database

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2024). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.00)OA: greenTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Danielle McQuinn,Meredith Hyun ORCID,KyungMann Kim ORCID,Vaishalee P. Kenkre ORCID,Saurabh Rajguru

Live enrichment

PubMed:39477701 PMC:PMC11934077 OpenAlex:https://openalex.org/W4403264349

National Cancer Institute

Grant: P30 CA014520

Genentech Inc

National Institutes of Health

Adaptive Biotechnologies

FWCI

0.00

Citation Percentile

0.2%

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11934077/

publisherhttps://api.elsevier.com/content/article/PII:S2152265024023589?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265024023589?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2024.09.014

Fields of Study

Lymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders researchCAR-T cell therapy researchHumansLymphoma, Mantle-CellNeoplasm, ResidualAgedFemaleMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overBendamustine HydrochlorideMaintenance ChemotherapyImmunotherapyAntibodies, Monoclonal, Humanized

MeSH Terms

Bendamustine HydrochlorideAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImmunotherapyMaleMiddle AgedNeoplasm, ResidualLymphoma, Mantle-CellMaintenance ChemotherapyAntibodies, Monoclonal, Humanized

Keywords

ChemoimmunotherapyMedicineMantle cell lymphomaOncologyInternal medicineResidualDiseaseLymphomaIbrutinibRituximabLeukemiaNext-generation SequencingBendamustineMinimal Residual DiseaseObinutuzumabMeasurable Residual Disease

Sustainable Development Goals

SDG 0: Zero hunger

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

FAIR Checklist

Authors (14)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)